Inmune Bio (INMB) EPS (Basic) (QoQ) (2018 - 2026)
Inmune Bio (INMB) EPS (Basic) (QoQ) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Inmune Bio | 61.32 Mn | 42.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.43% |
| Mar 31, 2026 | 6.07% |
| Dec 31, 2025 | 25.15% |
| Sep 30, 2025 | 69.39% |
| Jun 30, 2025 | -23.84% |
| Mar 31, 2025 | -62.83% |
| Dec 31, 2024 | 93.25% |
| Sep 30, 2024 | -633.15% |
| Jun 30, 2024 | 44.99% |
| Mar 31, 2024 | -275.06% |
| Dec 31, 2023 | 30.87% |
| Sep 30, 2023 | -89.90% |
| Jun 30, 2023 | -0.10% |
| Mar 31, 2023 | -8.13% |
| Dec 31, 2022 | 98.78% |
| Sep 30, 2022 | -7,669.49% |
| Jun 30, 2022 | 1.29% |
| Mar 31, 2022 | 34.10% |
| Dec 31, 2021 | 81.23% |
| Sep 30, 2021 | 0.76% |